Literature DB >> 25450066

Progress in the delivery of nanoparticle constructs: towards clinical translation.

Sinéad M Ryan1, David J Brayden2.   

Abstract

The application of nanoparticle constructs in drug delivery and nanomedicine is anticipated to have a great impact on future public health. Progress in this area is expected to address some of modern medicine's unresolved problems and recent literature contains many articles discussing this topic. We focus here on recent nanomedicine developments mainly in relation to cancer, which have either being approved for the market or clinical trials. We review nanomedicines in clinical use, nano-construct delivery systems (both non-targeted and targeted), imaging agents, as well as theranostics.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25450066     DOI: 10.1016/j.coph.2014.09.019

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  7 in total

1.  Experimental challenges regarding the in vitro investigation of the nanoparticle-biocorona in disease states.

Authors:  Sherleen Xue-Fu Adamson; Zhoumeng Lin; Ran Chen; Lisa Kobos; Jonathan Shannahan
Journal:  Toxicol In Vitro       Date:  2018-05-05       Impact factor: 3.500

2.  Controlling Release of Integral Lipid Nanoparticles Based on Osmotic Pump Technology.

Authors:  Zhiqiang Tian; Qin Yu; Yunchang Xie; Fengqian Li; Yi Lu; Xiaochun Dong; Weili Zhao; Jianping Qi; Wei Wu
Journal:  Pharm Res       Date:  2016-05-09       Impact factor: 4.200

3.  Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice.

Authors:  Susumu Ishiguro; Shuang Cai; Deepthi Uppalapati; Katie Turner; Ti Zhang; Wai Chee Forrest; M Laird Forrest; Masaaki Tamura
Journal:  Pharm Res       Date:  2016-06-22       Impact factor: 4.200

4.  From the Cover: Disease-Induced Disparities in Formation of the Nanoparticle-Biocorona and the Toxicological Consequences.

Authors:  Jonathan H Shannahan; Kristofer S Fritz; Achyut J Raghavendra; Ramakrishna Podila; Indushekar Persaud; Jared M Brown
Journal:  Toxicol Sci       Date:  2016-06-02       Impact factor: 4.849

5.  Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.

Authors:  Sang Joon Lee; Young-Il Jeong; Hyung-Kyu Park; Dae Hwan Kang; Jong-Suk Oh; Sam-Gyu Lee; Hyun Chul Lee
Journal:  Int J Nanomedicine       Date:  2015-08-28

6.  Role of prostacyclin in pulmonary hypertension.

Authors:  Jane A Mitchell; Blerina Ahmetaj-Shala; Nicholas S Kirkby; William R Wright; Louise S Mackenzie; Daniel M Reed; Nura Mohamed
Journal:  Glob Cardiol Sci Pract       Date:  2014-12-31

Review 7.  Albumin Nanovectors in Cancer Therapy and Imaging.

Authors:  Alessandro Parodi; Jiaxing Miao; Surinder M Soond; Magdalena Rudzińska; Andrey A Zamyatnin
Journal:  Biomolecules       Date:  2019-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.